Accountability


Exxon’s Early Knowledge of Climate Risks, Their Long Campaign of Climate Deception and Why It Matters

, director of science & policy

Internal Exxon memos recently brought to light through meticulous investigative reporting by Inside Climate News (ICN) show that senior company executives knew by 1978 that emissions of carbon dioxide from fossil fuels posed significant risks of disrupting the climate. Read more >

Bookmark and Share

The Science Community Must Fight Attacks on Science-Based Regulations

, director, Center for Science & Democracy

It is easy in the day-to-day work of science to miss the struggle now being waged in Washington over the role science plays in crafting health and safety protections for America. But that struggle is heating up and the outcome matters not only for the science community but for the country. The Center for Science and Democracy at UCS, and our Steering Committee of eminent scientists and public servants, are asking you to join the fight in a Policy Forum article published in Science May 29th.
Read more >

Bookmark and Share

“Hide No Harm” Bill Will Tip the Balance in Favor of Science and Safety over Corporate Profits

, , sr. Washington rep., Center for Science & Democracy

On July 16, Senators Richard Blumenthal (CT), Tom Harkin (IA) and Robert Casey (PA) introduced S. 2615, the “Hide No Harm Act.” Their legislation would impose criminal penalties—fines and even imprisonment—on corporate executives if they knowingly failed to warn the public about life-threatening dangers in their products. Read more >

Bookmark and Share

Sometimes the Good Guys Win: Unmasking “Company Doe”

, , sr. Washington rep., Center for Science & Democracy

Last week a federal district appeals court issued a decision that is a victory for scientific integrity, transparency,  and consumer protection. Read more >

Bookmark and Share

Spring Brings Hope–Even about Transparency and Accountability in Government

, , sr. Washington rep., Center for Science & Democracy

There is some good, albeit modest, news about the Food and Drug Administration and the way the agency addresses conflicts of interest on FDA advisory panels that consider the safety and efficacy of drugs and medical devices. Read more >

Bookmark and Share